NuAge Vision, a new company - the brainchild of Drs Pete Hotten and Nick Pay, was created to energize open innovation in the life science and biotechnology sectors. The essence of our business model is to: Advise, Conceive, Agree, Formulate and “Do” what is necessary to meet the clients’ objectives. NuAge Vision helps bring to market technologies developed in all technology led sectors but with a particular focus in Biological & Life Sciences. With impressive track records, the NuAge Vision principals are highly skilled in identifying winners and accessing the essential partners to deliver the technology to the marketplace. The concept is straightforward - with our level of experience and our skill set we are able to offer:
|•||Assessments of the technology potential, competition and market|
|•||Development of commercialization models and value added IP strategies and IP road-mapping|
|•||Guidance during the funding process including introductions to potential sources of funds|
|•||Mediation with key specialist advisors|
|•||Insight and leads to international / European markets|
Our idea is to help from initial idea to commercially products - from start-ups: by offering our experience (the pioneering process) , to assisting those searching (seeking) for new technologies by scouring the technology landscape and bring interesting companies to the their attention, through to providing value added services to potential investors in these fields and to align ourselves with the top technology support companies available.
Biopics of the principals.
Dr Nick Pay: includes 4 years (of 6 total) with Roche Diagnostics as senior vice president for strategic planning and subsequent roles with Kalibrant and Oxford Gene Technology during which he was responsible for the strategic development of the business. During his career Nick has led local(UK) sales and marketing organization for Becton Dickinson, Bayer and Roche as well as heading up the European Business Operation for Becton Dickinson. Nick has global experience having lived and worked abroad for nearly 10years.
Dr Pete Hotten: More than 20 years at board level with a range of start-up and more mature technology-led SME’s. During his career Peter has been MD / CEO of companies specializing in transferring technology from government research into the private sector (Rowett Research Services Ltd and Ploughshare Innovations Ltd), 10 years as a main board director of a leading DNA microarray company (Oxford Gene Technology) plus involvement in creating new companies from the perspective of both the technology owner (e.g. Oxford University) and private equity. Recent positions include being Interim CEO of Edinburgh Research and Innovations Ltd, CEO of Ploughshare Innovations and non-executive director of Subsea Asset Location Technologies Ltd.